866
Views
56
CrossRef citations to date
0
Altmetric
Research Paper

Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells

Pages 1228-1236 | Published online: 01 Jul 2009
 

Abstract

Increasing evidence suggests that cancer cells (relative to normal cells) have altered mitochondrial

electron transport chains (ETC) that are more likely to form reactive oxygen species (ROS; i.e. O2

•-and H2O2) resulting in a condition of chronic metabolic oxidative stress, that maybe compensated for

by increasing glucose and hydroperoxide metabolism. In the current study, the ability of an inhibitor of

glucose metabolism, 2-deoxy-D-glucose (2DG), combined with mitochondrial electron transport chain

blockers (ETCBs) to enhance oxidative stress and cytotoxicity was determined in human colon

cancer cells. Treatment of HT29 and HCT116 cancer cells with Antimycin A (Ant A) or rotenone (Rot)

increased carboxy-dichlorodihydrofluorescein diacetate (H2DCFDA) and dihydroethidine (DHE)

oxidation, caused the accumulation of glutathione disulfide and enhanced 2DG-induced cell killing. In

contrast, Rot did not enhance the toxicity of 2DG in normal human fibroblasts supporting the

hypotheses that cancer cells are more susceptible to inhibition of glucose metabolism in the presence

of ETCBs. In addition, 2-methoxy-antimycin A (Meth A; an analog of Ant A that does not have ETCB

activity) did not enhance 2DG-induced DHE oxidation or cytotoxicity in cancer cells. Finally, in HT29

tumor bearing mice treated with the combination of 2DG (500 mg/kg) + Rot (2 mg/kg) the average

rate of tumor growth was significantly slower when compared to control or either drug alone. These

results show that 2DG-induced cytotoxicity and oxidative stress can be significantly enhanced by

ETCBs in human colon cancer cells both in vitro and in vivo.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.